Adagene (ADAG) Competitors

Adagene logo
$1.48 -0.12 (-7.50%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.48 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ADAG vs. MYGN, VALN, RGNX, DMAC, and NGNE

Should you buy Adagene stock or one of its competitors? Adagene's main competitors and comparable companies include Myriad Genetics (MYGN), Valneva (VALN), REGENXBIO (RGNX), DiaMedica Therapeutics (DMAC), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adagene compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Myriad Genetics had 6 more articles in the media than Adagene. MarketBeat recorded 8 mentions for Myriad Genetics and 2 mentions for Adagene. Adagene's average media sentiment score of 1.12 beat Myriad Genetics' score of 0.81 indicating that Adagene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Adagene has lower revenue, but higher earnings than Myriad Genetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$824.50M0.64-$365.90M-$1.36N/A
Adagene$7.67M12.74-$17.61MN/AN/A

Myriad Genetics presently has a consensus price target of $5.98, suggesting a potential upside of 7.92%. Adagene has a consensus price target of $8.25, suggesting a potential upside of 457.43%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adagene has a net margin of 0.00% compared to Myriad Genetics' net margin of -16.07%. Adagene's return on equity of 0.00% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-16.07% -19.87% -9.67%
Adagene N/A N/A N/A

Myriad Genetics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Adagene has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Adagene beats Myriad Genetics on 10 of the 14 factors compared between the two stocks.

How does Adagene compare to Valneva?

Adagene (NASDAQ:ADAG) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

9.5% of Adagene shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Adagene has higher earnings, but lower revenue than Valneva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adagene$7.67M12.74-$17.61MN/AN/A
Valneva$197.56M2.68-$130.33M-$2.11N/A

In the previous week, Valneva had 1 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Valneva and 2 mentions for Adagene. Adagene's average media sentiment score of 1.12 beat Valneva's score of 0.40 indicating that Adagene is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Valneva
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adagene has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Valneva has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Adagene has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Adagene's return on equity of 0.00% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
AdageneN/A N/A N/A
Valneva -110.33%-153.20%-39.50%

Adagene presently has a consensus price target of $8.25, indicating a potential upside of 457.43%. Valneva has a consensus price target of $9.30, indicating a potential upside of 67.12%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Adagene beats Valneva on 10 of the 14 factors compared between the two stocks.

How does Adagene compare to REGENXBIO?

Adagene (NASDAQ:ADAG) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

9.5% of Adagene shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, REGENXBIO had 3 more articles in the media than Adagene. MarketBeat recorded 5 mentions for REGENXBIO and 2 mentions for Adagene. Adagene's average media sentiment score of 1.12 beat REGENXBIO's score of 0.02 indicating that Adagene is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
REGENXBIO
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adagene presently has a consensus price target of $8.25, suggesting a potential upside of 457.43%. REGENXBIO has a consensus price target of $23.18, suggesting a potential upside of 220.19%. Given Adagene's higher possible upside, equities analysts clearly believe Adagene is more favorable than REGENXBIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

Adagene has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Adagene has higher earnings, but lower revenue than REGENXBIO.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adagene$7.67M12.74-$17.61MN/AN/A
REGENXBIO$170.44M2.81-$193.88M-$3.21N/A

Adagene has a net margin of 0.00% compared to REGENXBIO's net margin of -113.85%. Adagene's return on equity of 0.00% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
AdageneN/A N/A N/A
REGENXBIO -113.85%-203.98%-42.54%

Summary

Adagene beats REGENXBIO on 8 of the 15 factors compared between the two stocks.

How does Adagene compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Adagene's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -94.56% -82.35%
Adagene N/A N/A N/A

DiaMedica Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 43.20%. Adagene has a consensus price target of $8.25, suggesting a potential upside of 457.43%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, DiaMedica Therapeutics had 12 more articles in the media than Adagene. MarketBeat recorded 14 mentions for DiaMedica Therapeutics and 2 mentions for Adagene. Adagene's average media sentiment score of 1.12 beat DiaMedica Therapeutics' score of 0.02 indicating that Adagene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DiaMedica Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Adagene has higher revenue and earnings than DiaMedica Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.76N/A
Adagene$7.67M12.74-$17.61MN/AN/A

DiaMedica Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Adagene has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Summary

Adagene beats DiaMedica Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Adagene compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Neurogene presently has a consensus price target of $79.57, indicating a potential upside of 244.47%. Adagene has a consensus price target of $8.25, indicating a potential upside of 457.43%. Given Adagene's higher possible upside, analysts clearly believe Adagene is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Adagene has higher revenue and earnings than Neurogene.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurogene$930K514.16-$90.35M-$5.09N/A
Adagene$7.67M12.74-$17.61MN/AN/A

Adagene's return on equity of 0.00% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
NeurogeneN/A -44.36% -40.61%
Adagene N/A N/A N/A

52.4% of Neurogene shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Neurogene had 11 more articles in the media than Adagene. MarketBeat recorded 13 mentions for Neurogene and 2 mentions for Adagene. Adagene's average media sentiment score of 1.12 beat Neurogene's score of 0.67 indicating that Adagene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurogene has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Adagene has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Neurogene and Adagene tied by winning 7 of the 14 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAG vs. The Competition

MetricAdageneBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$105.68M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / Sales12.7415.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book1.974.184.453.72
Net Income-$17.61M-$24.15M$3.52B$393.10M
7 Day Performance-30.52%-7.81%-5.93%-5.77%
1 Month Performance-28.16%-5.99%-4.58%-7.14%
1 Year Performance-25.38%-8.09%-1.94%-7.46%

Adagene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAG
Adagene
3.3267 of 5 stars
$1.48
-7.5%
$8.25
+457.4%
-18.7%$105.68M$7.67MN/A128
MYGN
Myriad Genetics
2.3673 of 5 stars
$5.67
-1.2%
$5.55
-2.1%
-16.8%$550.59M$824.50MN/A2,700
VALN
Valneva
2.3553 of 5 stars
$5.87
+3.7%
$9.30
+58.4%
-37.2%$538.77M$197.56MN/A674
RGNX
REGENXBIO
2.7867 of 5 stars
$7.69
-4.7%
$23.18
+201.5%
-35.0%$532.73M$153.91MN/A371
DMAC
DiaMedica Therapeutics
1.8868 of 5 stars
$9.67
+0.2%
$12.00
+24.1%
+30.7%$520.38MN/AN/A35

Related Companies and Tools


This page (NASDAQ:ADAG) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners